AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...

A unit of AstraZeneca Plc is facing a new antitrust suit claiming the company monopolized the market for a blood disorder ...

Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...